A new study examined randomized trials of glucose-lowering drugs, including SGLT2 inhibitors and GLP-1 agonists, and assessed drug effectiveness for four categories of patients: diabetes drug-naive or those taking metformin at low or high risk of cardiovascular disease (CVD). Read more